PLoS ONE (Jan 2014)

Overexpression of cohesion establishment factor DSCC1 through E2F in colorectal cancer.

  • Kiyoshi Yamaguchi,
  • Rui Yamaguchi,
  • Norihiko Takahashi,
  • Tsuneo Ikenoue,
  • Tomoaki Fujii,
  • Masaru Shinozaki,
  • Giichiro Tsurita,
  • Keisuke Hata,
  • Atsushi Niida,
  • Seiya Imoto,
  • Satoru Miyano,
  • Yusuke Nakamura,
  • Yoichi Furukawa

DOI
https://doi.org/10.1371/journal.pone.0085750
Journal volume & issue
Vol. 9, no. 1
p. e85750

Abstract

Read online

Ctf18-replication factor C complex including Dscc1 (DNA replication and sister chromatid cohesion 1) is implicated in sister chromatid cohesion, DNA replication, and genome stability in S. cerevisiae and C. elegans. We previously performed gene expression profiling in primary colorectal cancer cells in order to identify novel molecular targets for the treatment of colorectal cancer. A feature of the cancer-associated transcriptional signature revealed from this effort is the elevated expression of the proto-oncogene DSCC1. Here, we have interrogated the molecular basis for deviant expression of human DSCC1 in colorectal cancer and its ability to promote survival of cancer cells. Quantitative PCR and immunohistochemical analyses corroborated that the expression level of DSCC1 is elevated in 60-70% of colorectal tumors compared to their matched noncancerous colonic mucosa. An in silico evaluation of the presumptive DSCC1 promoter region for consensus DNA transcriptional regulatory elements revealed a potential role for the E2F family of DNA-binding proteins in controlling DSCC1 expression. RNAi-mediated reduction of E2F1 reduced expression of DSCC1 in colorectal cancer cells. Gain- and loss-of-function experiments demonstrated that DSCC1 is involved in the viability of cancer cells in response to genotoxic stimuli. We reveal that E2F-dependent expression of DSCC1 confers anti-apoptotic properties in colorectal cancer cells, and that its suppression may be a useful option for the treatment of colorectal cancer.